References
- Wallace DV, Dykewicz MS, Bernstein DI et al. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin. Immunol. 122(2 Suppl.), S1–S84 (2008).
- Nathan RA, Meltzer EO, Derebery J et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc. 29, 600–608 (2008).
- Dalal AA, Stanford R, Henry H, Borah B. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann. Allergy Asthma Immunol. 101, 23–29 (2008).
- Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 31, 375–380 (2010).
- Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 22, 345–361 (2004).
- Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patient quality of life: findings from the nasal allergy survey assessing limitations. J. Fam. Pract. 61( Suppl. 1), S5–S10 (2012).
- Portnoy JM, Van Osdol T, Williams PB. Evidence-based strategies for treatment of allergic rhinitis. Curr. Allergy Asthma Rep. 4, 439–446 (2004).
- Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 126, 466–476 (2010).
- Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 129, 1282–1289 (2012).
- Physician Survey Sponsored by the American College of Allergy, Asthma & Immunology. Harris Interactive Inc., Rochester, NY 19–21 October 2001.
- Ratner PH, Hampel F, Van Bavel J et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 100, 74–81 (2008).
- Hampel FC, Ratner PH, Van Bavel J et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann. Allergy Asthma Immunol. 105, 168–173 (2010).
- Berger W, Shah S, Lieberman P et al. Long-term safety study of MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. JACI: In Practice (2013) ( In Press).
- Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy 21, 77–83 (1990).
- Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 110, 1189–1193 (2000).
- Cordray S, Harjo JB, Miner L. Comparison of intranasal hypertonic Dead Sea saline spray and intranasal aqueous triamcinolone spray in seasonal allergic rhinitis. Ear Nose Throat J. 84, 426–430 (2005).
- Barnes ML, Vaidyanathan S, Williamson PA, Lipworth J. The minimal clinically important difference in allergic rhinitis. Allergy 40, 242–250 (2010).
- Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 33, 324–332 (2012).
- Srinivasan M, Rahmathullah R, Blair CR et al. Cataract progression in India. Br. J. Ophthalmol. 81(10), 896–900 (1997).
- Orban NT, Saleh H, Durham SR. Middleton’s Allergy Principles & Practice (7th Edition). Adkinson NF Jr, Bochner BS, Busse WW, Holgate ST, Lemanske RF Jr, Simons FER ( Eds). Allergic and non-allergic rhinitis, 980 (2009).
- Davies RJ, Bagnall AC, McCabe RN, Calderon MA, Wang JH. Antihistamines: topical vs oral administration. Clin. Exp. Allergy 26( Suppl. 3), 11–17 (1996).
- Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1-receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann. Allergy Asthma Immunol. 89, 479–484 (2002).
- Ciprandi G, Pronzato C, Passalacqua G et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cell: an antiallergic activity. J. Allergy Clin. Immunol. 98, 1088–1096 (1996).
- Dymista™, package insert. Meda Pharmaceuticals, Somerset, NJ USA.
- Dymista™, Summary of Product Characteristics. Meda Pharmaceuticals, Takeley, Bishop's Stortford, UK (2013).
Websites
- HealthSTAR Communications in partnership with Schulman, Ronca & Bucuvales Inc. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. www.mmcpub.com/scsaia/adult.pdf
- The nasal allergy survey assessing limitations. TEVA Respiratory, LLC. www.nasalsurvey.com/Default.aspx2010.
- FDA guideline. Guidance for industry. Allergic rhinitis: clinical development programs for drug programs. US Department of Health and Human Services, FDA Center for Drug Evaluation and research. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071293.pdf ( Accessed April 2000)
- EMA guideline. Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. CHMP/EWP/2455/02. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/9/WC500003554.pdf ( Accessed October 2004)